BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:BIO - US0905722072 - Common Stock
296.57 USD
-8.65 (-2.83%)
296.57 USD
0 (0%)
Taking everything into account, BIO scores 4 out of 10 in our fundamental rating. BIO was compared to 58 industry peers in the Life Sciences Tools & Services industry. BIO has an excellent financial health rating, but there are some minor concerns on its profitability. BIO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year BIO was profitable.
- In the past year BIO had a positive cash flow from operations.
- In multiple years BIO reported negative net income over the last 5 years.
- BIO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- BIO has a Return On Assets (-6.97%) which is in line with its industry peers.
- BIO has a Return On Equity of -10.03%. This is comparable to the rest of the industry: BIO outperforms 52.63% of its industry peers.
- BIO's Return On Invested Capital of 2.26% is fine compared to the rest of the industry. BIO outperforms 61.40% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for BIO is significantly below the industry average of 13.29%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
- With a decent Operating Margin value of 10.27%, BIO is doing good in the industry, outperforming 70.18% of the companies in the same industry.
- In the last couple of years the Operating Margin of BIO has remained more or less at the same level.
- With a decent Gross Margin value of 52.42%, BIO is doing good in the industry, outperforming 63.16% of the companies in the same industry.
- In the last couple of years the Gross Margin of BIO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
- BIO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- Compared to 1 year ago, BIO has less shares outstanding
- Compared to 5 years ago, BIO has less shares outstanding
- Compared to 1 year ago, BIO has a worse debt to assets ratio.
2.2 Solvency
- BIO has an Altman-Z score of 3.34. This indicates that BIO is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 3.34, BIO is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
- The Debt to FCF ratio of BIO is 3.57, which is a good value as it means it would take BIO, 3.57 years of fcf income to pay off all of its debts.
- BIO's Debt to FCF ratio of 3.57 is fine compared to the rest of the industry. BIO outperforms 77.19% of its industry peers.
- BIO has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
- The Debt to Equity ratio of BIO (0.18) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.34 |
ROIC/WACC0.21
WACC10.76%
2.3 Liquidity
- BIO has a Current Ratio of 5.44. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
- BIO has a better Current ratio (5.44) than 85.96% of its industry peers.
- BIO has a Quick Ratio of 3.94. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of BIO (3.94) is better than 68.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
- The earnings per share for BIO have decreased by -1.90% in the last year.
- BIO shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.84% yearly.
- The Revenue has decreased by -0.88% in the past year.
- The Revenue has been growing slightly by 2.11% on average over the past years.
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
3.2 Future
- Based on estimates for the next years, BIO will show a decrease in Earnings Per Share. The EPS will decrease by -2.66% on average per year.
- The Revenue is expected to grow by 1.26% on average over the next years.
EPS Next Y-2.48%
EPS Next 2Y-0.29%
EPS Next 3Y3.33%
EPS Next 5Y-2.66%
Revenue Next Year0.04%
Revenue Next 2Y1.13%
Revenue Next 3Y1.96%
Revenue Next 5Y1.26%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 28.77 indicates a quite expensive valuation of BIO.
- Based on the Price/Earnings ratio, BIO is valued a bit cheaper than 73.68% of the companies in the same industry.
- When comparing the Price/Earnings ratio of BIO to the average of the S&P500 Index (27.21), we can say BIO is valued inline with the index average.
- A Price/Forward Earnings ratio of 28.93 indicates a quite expensive valuation of BIO.
- Based on the Price/Forward Earnings ratio, BIO is valued a bit cheaper than the industry average as 71.93% of the companies are valued more expensively.
- When comparing the Price/Forward Earnings ratio of BIO to the average of the S&P500 Index (25.98), we can say BIO is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.77 | ||
| Fwd PE | 28.93 |
4.2 Price Multiples
- Based on the Price/Free Cash Flow ratio, BIO is valued cheaper than 84.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.76 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.67
EPS Next 2Y-0.29%
EPS Next 3Y3.33%
5. Dividend
5.1 Amount
- BIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BIO-RAD LABORATORIES-A / BIO FAQ
What is the fundamental rating for BIO stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.
Can you provide the valuation status for BIO-RAD LABORATORIES-A?
ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES-A (BIO). This can be considered as Overvalued.
What is the profitability of BIO stock?
BIO-RAD LABORATORIES-A (BIO) has a profitability rating of 4 / 10.
Can you provide the expected EPS growth for BIO stock?
The Earnings per Share (EPS) of BIO-RAD LABORATORIES-A (BIO) is expected to decline by -2.48% in the next year.